Oxecta now commercially available

PALATINE, Ill. — A pain medication that utilizes Acura Pharmaceuticals' Aversion technology now is commercially available.

Acura said it was informed by Pfizer that Oxecta has hit the market in 5-mg and 7.5-mg strengths, which will be sold in 100-count bottles. Oxecta is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.

"The commercial availability of Oxecta is an important milestone and we are pleased Pfizer continues to advance the commercialization plan for Oxecta," Acura CEO Bob Jones said.

Acura has exclusively licensed the Aversion technology to Pfizer in the United States, Canada and Mexico for use in four opioid-based pain products.

Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.